相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Massachusetts General Hospital has enrolled the first patient in a trial evaluating RELiZORB's efficacy in managing exocrine pancreatic insufficiency in tube-fed pancreatitis patients. - RELiZORB is the only FDA-cleared enzyme device designed to mimic pancreatic lipase function, improving fat absorption for tube-fed patients with malabsorptive conditions. - This investigator-initiated trial is one of four ongoing clinical studies evaluating RELiZORB's safety and efficacy across various malabsorptive conditions, including pancreatitis, short bowel syndrome, and critical care.
- Quantum BioPharma and Massachusetts General Hospital have successfully scanned the first multiple sclerosis patient using a novel [18F]3F4AP PET imaging technique designed to monitor demyelination. - The study utilizes a newly installed combined GE Signa PET-MR scanner at MGH that allows simultaneous acquisition of PET and MRI signals, improving spatial and temporal coregistration. - Previous animal and human studies demonstrated that [18F]3F4AP was highly sensitive to demyelinated lesions with favorable pharmacokinetics, suggesting promise as a biomarker for monitoring treatment responses. - The imaging technique may enhance the development of remyelinating and neuroprotective drugs for MS, including Quantum BioPharma's lead compound Lucid-MS.
